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Serum and urinary concentrations of heparan sulfate in patients of increased glomerular albumin flux is unknown. We
with diabetic nephropathy. have suggested a schema of possible mechanisms leading
Background. Heparan sulfate (HS) contributes to the nega- to albuminuria in diabetes [3]. Diabetic nephropathy
tive charge in the glomerular basement membrane (GBM),
is histologically characterized by glomerular basementwhich may maintain the GBM charge barrier. Changes in sul-
membrane (GBM) thickening and mesangial expansionfation and/or the concentration of HS may be associated with
the development of diabetic nephropathy. caused by defective remodeling of the extracellular ma-
Methods. Using two different antibodies specific for HS trix (ECM), namely, an increased amount of type IV
chains, one that reacts with the N-sulfated sequences in HS collagen, laminin, and fibronectin, and a relative or abso-
chains (10E4) and the other that reacts with neo-epitope of
lute decreased amount of heparan sulfate proteoglycanHS, which occurs after heparitinase digestion of HS chains
(HSPG) [3]. Poor metabolic control could induce in-(3G10), we examined the serum and urinary concentrations of
creased intraglomerular pressure [4] and overproductionHS by enzyme-linked immunosorbent assay and performed
immunohistochemical staining of glomeruli in diabetic patients of advanced glycated proteins and of several growth fac-
with and without nephropathy. tors such as transforming growth factor-b and angioten-
Results. The level of urinary excretion of 10E4 binding HS/ sin II, and these may affect the structural compositioncreatinine clearance was significantly reduced in diabetic pa-
of the ECM proteins [3]. The defective remodeling oftients when compared with that in nondiabetic subjects (P ,
the ECM, such as accumulation of ECM proteins with0.0001), and the level was more decreased in patients with
overt nephropathy than in patients without overt nephropathy. relative decrease of HSPG [3], may lead to a loss of
No differences or only small differences were found between glomerular charge selectivity [5] and altered glomerular
these groups in serum and urinary 3G10-binding HS and in size selectivity [6], allowing albumin leakage [3].serum 10E4-binding HS. Immunohistochemical staining with
Albuminuria can be induced by the injection of anti-these antibodies was consistent with the findings in the urine.
bodies to heparan sulfate (HS) [7] or by the enzymaticConclusions. The results suggest that a decreased HS N-sul-
fation exists in the urine, which may reflect a structural change digestion of HS in the GBM [8]. Vernier et al showed
or an altered processing of HS within the GBM. Because N- a reduction of HS-associated anionic sites within the
sulfation plays a key role in determining the extent of sulfation GBM in diabetic nephropathy, where they demonstrated
within the HS chains, the decreased urinary 10E4-binding HS an inverse correlation between the degree of albumin-may have potential implications with regard to the develop-
uria and the number of anionic sites [9]. HSPGs consistment of diabetic nephropathy.
of sulfate groups distributed along glycosaminoglycan
(GAG) side chains [10, 11], and these may, among other
molecules, maintain a negative charge in the GBM [12–Albuminuria is the first clinical finding in diabetic pa-
14]. These suggest that albuminuria is associated with atients who are developing diabetic nephropathy [1].
decrease in HS-associated negative charge within theWhile albuminuria is of glomerular origin [2], the cause
GBM.
The extent of negative charge within HS polysaccha-
rides varies considerably according to the degree of sul-Key words: glomerular basement membrane, diabetes, sulfation,
charge barrier, extracellular matrix. fation [15–17]. The biosynthesis of HS involves the for-
mation of a nonsulfated precursor polysaccharide, whichReceived for publication December 11, 1998
subsequently undergoes a series of polymer-modificationand in revised form February 19, 1999
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residues, which is followed by the C-5 epimerization of nephropathy in the kidneys or renal tract were excluded.
Patients who had an elevated serum concentration ofD-glucuronic acid (GlcA) to iduronic acid units, and
finally by O-sulfation at various positions [17]. The GlcA creatinine (. 1.5 mg/dl) were also excluded. A group of
nondiabetic subjects who were normoalbuminuric andC-5 epimerization and O-sulfation reactions occur in the
close vicinity of N-sulfate groups [15–17]. Therefore, N comparable with diabetic patients with respect to age
and sex was recruited from the health examination clinicsulfation is likely to play a key role in determining the
overall extent of sulfation within the HS chains. of the Nomura Hospital (Tokyo, Japan), and served as
a control group. None of the subjects had other seriousIt has been shown that the sulfation of liver HS is
lowered in diabetes [18]. Several reports have indicated diseases (for example, liver dysfunction, cancer, or
chronic pyelonephritis).that the activity of glucosaminyl N-deacetylase, a key
enzyme important for the step of N-deacetylation/N- We studied kidney tissue that remained from open
renal biopsy or nephrectomy samples obtained from pa-sulfation of GlcNAc residues [19], is impaired in diabe-
tes. Glucosaminyl N-deacetylase activity was approxi- tients undergoing diagnostic or surgical evaluation at
the Tokai University School of Medicine. Normal renalmately 40% lower in haptocytes from streptozotocin-
induced diabetic rats as compared with control cells [20]. tissues were obtained from nondiabetic subjects with
renal carcinoma. The analysis included three nondiabeticThe effect of poor metabolic control on the inhibition
of glomerular glucosaminyl N-deacetylase activity was subjects, three normoalbuminuric diabetic, and five
patients with diabetic nephropathy. The diagnosis of dia-shown in diabetic rats [21–23] and in cultured fibroblasts
from diabetic patients with nephropathy [24]. These betic nephropathy was confirmed by persistent protein-
uria, absence of nondiabetic renal disease, and patho-findings suggest that impaired sulfation of HS chains may
be associated with diabetes and with the development of logical evaluation of renal biopsy specimens by light
microscopy. Renal biopsies were performed with an ap-diabetic nephropathy.
It is, however, unknown whether changes in the sul- proval from the Regional Ethics Committee.
fation of HS chains or in the concentration of HS occur
Measurement of clinical parametersin diabetes and in the development of diabetic nephropa-
thy. In this study, we examined serum and urinary con- The urinary albumin excretion was measured using a
radioimmunoassay technique [26]. Blood pressure wascentrations of HS using two different antibodies specific
for HS, one that reacts with N-sulfated sequences of measured using a standard sphygmomanometer with an
appropriately sized cuff, with the subject in a supineHS chains and the other that reacts with neo-epitope
of HS, which is generated after heparitinase digestion position in the morning. The average of three measure-
ments was recorded. Blood samples were obtained inof HS. The aim of this study is to investigate whether
changes in sulfation and/or the concentration of HS is the fasting state. Serum and urinary concentrations of
creatinine were measured using Jaffe’s method. Glomer-associated with diabetes and diabetic nephropathy.
ular filtration rate (GFR) was calculated using Cockkroft
and Gault’s formula. Serum concentrations of total cho-
METHODS
lesterol and triglyceride were measured by enzymatic
Subjects colorimetric methods using an automated multianalyzer
(7450 Hitachi; Hitachi, Tokyo, Japan). Fasting blood glu-Patients with non–insulin-dependent diabetes mellitus
(NIDDM) were recruited from the outpatient clinic of cose levels were measured by glucose oxidase method
using the Glucose Auto&Stat (GA-1140; Kyoto Daiichithe Diabetes Center, Tokyo Women’s Medical Univer-
sity School of Medicine, Tokyo, Japan. The diagnosis of Kagaku, Kyoto, Japan). Glycated hemoglobin (HbA1c)
was measured by high-performance liquid chromatogra-NIDDM was made according to the criteria of the World
Health Organization [25]. They were divided into three phy (HPLC; HA8131; Kyoto Daiichi Kagaku). The in-
terassay variation coefficients were 5 to 8% for all assays.groups according to the level of urinary albumin excre-
tion rate (AER) obtained on the basis of the median
Measurement of heparan sulfate by ELISAAER from three first-morning collections at home; pa-
tients with normoalbuminuria (AER , 12 mg/g·Cr), pa- Two monoclonal antibodies specific for HS-related
epitopes were used for the measurement of HS. Onetients with incipient nephropathy (AER 12 to 220 mg/
g·Cr), and patients with clinical nephropathy (AER . was mAb 10E4 (mouse IgM, code no. 370255; Seikagaku
Corporation, Tokyo, Japan) [27], which reacts with an220 mg/g·Cr). The albumin to creatinine ratio in the first-
morning urine at 12 and 220 mg/g·Cr corresponded to epitope that occurs in native HS chains and that is de-
stroyed by N desulfation of the GAG. The antibody doesthe 24-hour urinary AER at 30 and 300 mg/24 hr, respec-
tively (data not shown). Patients with increased albumin- not react with hyaluronate, or chondroitin sulfate, and
the reactivity of proteoglycan extract or tissue sectionsuria who had no diabetic retinopathy or who had clinical
or laboratory evidence of disease other than diabetic with the 10E4 antibody is completely abolished by hepar-
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itinase [22]. The other was mAb 3G10 (mouse IgG, code
no. 370260; Seikagaku) [27], which reacts with desatu-
rated uronic acid residues of the polysaccharide chains
after heparitinase digestion of the proteoglycan. The re-
activity of proteoglycan extract or tissue sections with the
3G10 antibody is destroyed by treatment with mercuric
acetate. The reactivity is not generated by treating pro-
teoglycans with heparinase or chondroitin sulfate lyases
[27]. The enzyme-linked immunosorbent assay (ELISA)
procedures were performed as follows. (a) Polystyrene
microtiter plates (Nunc-Immuno Plate, Roskilde, Den-
mark) were precoated with 50 ml of 0.02 mg/ml mAb
10E4 or 3G10 in phosphate-buffered saline (PBS), pH
7.4, per well during an overnight incubation at 48C. (b)
After washing three times with PBS, 200 ml of PBS con-
taining 1% bovine serum albumin (BSA) were added Fig. 1. Fluid phase inhibition of 10E4 biding to chemically modified
and incubated for two hours at room temperature. (c) heparan sulfate (HS). Symbols are: (d) HS, heparan sulfate containing
N-sulfate, 6-O-sulfate, and 2-O-sulfate; (j) CDSNAc-HS, completelyStandard antigen solution was prepared using HS ob-
desulfated, N-acetylated HS; (m) CDSNS-HS, completely desulfated,tained from bovine kidney (code no. 400700; Seikagaku) N-sulfated HS; (X) NDSNAc-HS, N-desulfated, N-acetylated HS.
in the range of 2.5 to 40 mg/ml in PBS containing 0.05%
Tween 20 and 1% BSA (PBS-TB). (d) After washing
with PBS containing 0.05% Tween 20 (PBS-T), 50 ml of
urine sample (diluted 1:20 in PBS-TB) or the standard to urine samples of which the HS concentration in the
range of 0 to 138 mg/ml (N 5 6) was 107.2 6 13.7%antigen solution was incubated for 45 minutes at 378C.
(e) Subsequently, 10 ml of 0.1 mg/ml of biotinylated HS (mean 6 sd). The intra-assay variations for the mAbs
10E4 and 3G10 reactive HS were 4.5 and 2.9% at a HSin PBS-TB was added and incubated for 45 minutes at
378C. The biotinylated HS was prepared as described by concentration of 2.5 mg/ml and 10.5 and 7.6% at a HS
concentration of 40.0 mg/ml, respectively. Day to dayYang, Yang, and Goetinck [28]. ( f) The plates were
washed three times with PBS-T. The bound biotinylated variations examined in 10 nondiabetic subjects over five
different days were 24.9% in 10E4 binding HS and 17.1%HS was detected by 50 ml of peroxidase conjugated strep-
tavidin (SA5004; Vector, Burlingame, CA, USA) diluted in AER. Time to time variations within a day, which
were examined in 10 nondiabetic subjects at four differ-1:1000 in PBS-TB. (g) After 30 minutes of incubation,
the plates were washed three times with PBS-T, followed ent times, were 26.1% in 10E4 binding HS and 23.7%
in AER.by 15 minutes of incubation with 50 ml of TMB (Tetra-
Methyl-Benzidine) solution. (h) The reaction was In the previously described inhibition ELISA using
urine and serum samples, mAb 10E4 binding to HS wasstopped by adding 50 ml of 1 N hydrochloric acid. (i)
The signal was measured at 450 nm, with a 630 nm abolished by pretreatment of samples with heparitinase,
whereas 3G10 mAb binding occurred after the pretreat-reference in a Titertek multiscan. ( j) Differences of ab-
sorbance between the buffer (containing null HS) and ment with heparitinase in ELISA. No or little reactivity
of 10E4 and 3G10 was observed with other GAGs suchthe standard (known concentration of HS) were calcu-
lated for drawing the standard curve. as chondroitin sulfate A, chondroitin sulfate C, keratan
sulfate, and hyaluronic acid.For the measurement of mAb 3G10 reactive HS con-
centration, pretreatment with 25 ml of heparitinase I (HS In order to determine the specificity of mAb-10E4
binding, serial concentrations of HS (containing N-sul-lyase, code 100704; Seikagaku) 2 mU/ml in 20 mm sodium
acetate containing 1% BSA at 378C, pH 7.0 was per- fate, 6-O-sulfate, and 2-O-sulfate), CDSNAc-HS (com-
pletely desulfated, N-acetylated HS), CDSNS-HS (com-formed (45-minute incubation) between procedure steps
(d) and (e). pletely desulfated, N-sulfated HS), and NDSNAc-HS
(N-desulfated, N-acetylated HS; Heparan Sulfate Chem-The finding that precoating with mouse IgM or IgG
instead of mAb 10E4 or 3G10 did not yield any reactivity ically Modified Kit, code 400646; Seikagaku) were added
(Fig. 1). The 10E4 antibody did not bind to completelyin these methods revealed that the reactivity was not
due to the nonspecific binding. Dilutions of the serum desulfated N-acetylated HS and N-desulfated N-ace-
tylated HS, and it only bound to HS that contained N-and urine samples (N 5 4) ranging from 1:20 to 1:100
demonstrated a close linearity with correlation coeffi- sulfate, 6-O-sulfate, and 2-O-sulfate and to completely
desulfated N-sulfated HS, pointing to a role for N-sul-cients of 0.990 to 0.997. The recovery of HS at a concen-
tration of 200 mg/ml (code no. 400700; Seikagaku) added fated sequences in 10E4 antibody recognition.
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Immunohistochemical staining (P , 0.0001), and the level was furthermore decreased
in patients with clinical nephropathy than the levels inParaffin-embedded sections cut at 4 mm were deparaf-
patients with normoalbuminuria and incipient nephropa-finized and washed in 0.01 m PBS. After combined pre-
thy (P , 0.005; Table 2). Serum concentration of 3G10-treatment with proteinase K (25530-049; GIBCO BRL,
binding HS was significantly lower in diabetic patientsRockville, MD, USA) and DNase (M610A; Promega,
than in nondiabetic controls (P , 0.05), whereas urinaryMadison, WI, USA), the sections were incubated with
excretion of 3G10-binding HS/CCr was similar among theprimary antibody (10E4 at 0.67 mg/ml and 3G10 at
four groups (Table 2).5 mg/ml) overnight at 48C. Pretreatment with hepariti-
Among diabetic patients, the urinary excretion ofnase I (50 mU/section) for two hours at 378C was also
10E4-binding HS/CCr correlated exclusively to the uri-performed when using 3G10. Peroxidase-conjugated
nary albumin excretion (r 5 20.29, P , 0.005), and itantimouse IgG and antimouse IgM were used as second-
had no correlations with the duration of diabetes, HbA1cary antibodies (Jackson ImmunoResearch, West Grove,
levels, fasting blood glucose levels, systolic and diastolicPA, USA). All dilutions were performed in approximate
blood pressure levels, and serum concentrations of totalbuffer according to the instructions of the manufacturer.
cholesterol and triglyceride. The use of antihypertensiveAll procedures were performed in one setting. For con-
agents, angiotensin-converting enzyme inhibitors, ortrol sections, nonimmune mouse IgG and IgM were used
antihyperlipidemic agents did not affect the level ofinstead of the primary antibodies. After the DAB reac-
10E4-binding HS.tion, each glomerulus was photographed (3400) and
numbered randomly in order to be examined without Immunohistochemical staining
knowledge of the sample origin. Five glomeruli were
Table 3 shows clinical characteristics of subjects whoselected as controls to score the staining scale (0 5 no
underwent open renal biopsies. On light microscopy,staining, 1 5 slightly positive, 2 5 positive, 3 5 positive
subjects 4 through 6 showed only mild mesangial expan-to strongly positive, 4 5 strongly positive staining), and
sion. Subjects 7 and 8 showed moderate mesangialstaining for the 10E4 and 3G10 epitope was scored by
expansion, and subjects 9 through 11 showed severe mes-five independent investigators.
angial expansion with nodular lesions. Figure 2 demon-
strates glomeruli immunohistochemically stained withStatistical analysis
mAb 10E4. In the control group, a linear to fine granularDifferences between the relevant groups were tested
pattern was observed (Fig. 2A, subject 1). In the diabeticusing the Student’s unpaired t-test for continuous vari-
group, the pattern varied from linear to granular to aables, with non-normally distributed variables first being
discontinuation of the linearity, and glomeruli from pa-logarithmically transformed. Pearson’s coefficients were
tients with diabetic nephropathy revealed residual (Fig.
calculated for correlation analyses. All analyses were run
2B, subject 8) or totally diminished staining (Fig. 2C,
on the personal computer statistics package SPSS for
subject 10). A mean of 19 glomeruli (/subject) was evalu-
Windows version 6.0.
ated blindly for scoring of staining intensity, and the
staining score is shown in Figure 3. The kidney sections of
the nondiabetic subjects (subjects 1 through 3) revealedRESULTS
staining of high intensity (2 to 4) with 10E4 antibody,Clinical characteristics of the subjects
whereas in those with diabetic nephropathy (subjects 7
Table 1 shows the subjects’ clinical and biochemical through 12), the staining was weak, with the scores rang-
characteristics. Systemic blood pressure levels increased ing from 0 to 2. Normoalbuminuric diabetic subjects
with increasing urinary AER, regardless of antihyperten- showed preserved (subject 4) or decreased (subjects 5
sive treatment. Diabetic patients exhibited lower serum and 6) staining as compared with nondiabetic subjects.
concentrations of total cholesterol as compared with No differences were found in 3G10 staining between the
nondiabetic subjects because of treatment with antihy- groups (data not shown).
perlipidemic agent, whereas serum concentrations of tri-
glyceride were similar among the groups. The levels of
DISCUSSIONGFR were similar among the groups.
This study showed that urinary excretion of 10E4-
Determinants of serum and urinary concentrations of binding HS was decreased in diabetic patients, as com-
10E4-binding and 3G10-binding HS pared with nondiabetic controls, and the decrease was
Serum concentrations of 10E4-binding HS were simi- furthermore pronounced in patients with diabetic ne-
lar among the four groups (Table 2). Urinary excretion phropathy. A decrease in 10E4 binding may indicate a
of 10E4-binding HS/CCr was significantly reduced in dia- reduction of N-sulfated sequences within the HS polysac-
charides, whereas HS determined by mAb 3G10 maybetic patients as compared with nondiabetic subjects
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Table 1. Clinical and biochemical characteristics of the subjects
Non-diabetic NIDDM with NIDDM with incipient NIDDM with overt
controls normoalbuminuria nephropathy nephropathy
N538 N533 N538 N 5 38
Group 1 Group 2 Group 3 Group 4
Age years 5566 55 612 58 69 55 614
Male sex N of patients (%) 19 (50) 18 (53) 25 (66) 24 (63)
Urinary albumin excretion mg/g Cr (range) 6.6 (4.6–8.8) 6.5 (4.8–8.9) 35.4 (19.2–92.9) 437 (326–850)
Body mass index kg/m2 22.562.1 22.1 63.5 23.7 63.1 23.5 63.6
Duration of diabetes years 1169 14 68 16 67
HbA1c % 4.960.3 8.8 62.1 8.6 62.2 8.1 61.9
Fasting blood glucose mg/dl 90610 148633 149 633 138 632
Systolic blood pressure mm Hg 111614 123 617a 130618b 142618b,c,d
Diastolic blood pressure mm Hg 71610 74 68 74 611 80 611a,b,c
Treatment with antihypertensive agent N of patients (%) 0 (0) 10 (30) 17 (45) 18 (47)
Treatment with angiotensin converting enzyme
inhibitors N of patients (%) 0 (0) 3 (9) 7 (18) 1 (3)
Serum creatinine mg/dl 0.860.2 0.9 60.2 0.9 60.2 1.0 60.2a,c,d
CCr ml/mine 77615 72 621 78 623 69 622
Total cholesterol mg/dl 222634 196 640 198 640 202 634a
Triglyceride mg/dl 110648 120 682 149 6136 133 670a
Treatment with antihyperlipidemic agent N of patients (%) 0 (0) 16 (47) 18 (47) 8 (21)
Data are mean 6 sd; except for urinary albumin excretion where median and interquartile range are given.
a P , 0.01 vs. Group 1, b P , 0.0001 vs. Group 1
c P , 0.05 vs. Group 2
d P , 0.05 vs. Group 3
e Calculated by Cockcroft and Gault’s formula
Table 2. Serum concentration and urinary excretion of 10E4 and 3G10 binding heparan sulfate
Non-diabetic NIDM with NIDDM with incipient NIDDM with overt
controls normoalbuminuria nephropathy nephropathy
Group 1 Group 2 Group 3 Group 4
Serum concentation of 10E4 binding HS lg/ml 162 (132–179) 176 (129–200) 151 (122–193) 154 (110–187)
Urinary excretion of 10E4 binding
HS/CCr 3 1023 lg 1300 (561–2000) 296 (129–471)a 250 (61–734)a 87 (37–197)a,b,c
Serum concentration of 3G10 binding HS lg/ml 21.8 (19.4–27.2) 19.0 (14.9–23.6)d 19.1 (14.1–23.3)d 20.0 (14.0–20.7)d
Urinary excretion of 3G10 binding 82 (47–171) 68 (40–96) 62 (40–79) 68 (41–98)
HS/CCr 3 1023 lg
Data are median and interquatile range. Urinary excretions are expressed as per ml of estimated filtration.
a P , 0.0001 vs. Group 1
b P , 0.005 vs. Group 2
c P , 0.005 vs. Group 3
d P , 0.005 vs. Group 1
Table 3. Clinical parameters at the time of open renal biopsy
Known duration Urinary
Age Sex of diabetes Serum creatinine HbA1c protein CCr
Subject No. years M/F years mg/dl % g/day ml /min /1.73m2
1 52 M — — — 0 —
2 58 M — — — 0 —
3 57 F — — — 0 —
4 15 M 1 0.5 14.6 0 100
5 36 F 5 0.5 7.3 0 113
6 51 M 10 0.7 7.6 0 80
7 31 M 3 1.0 10.3 2.8 62
8 63 M 2 1.0 6.8 3.2 89
9 46 M 2 0.9 7.4 4.6 32
10 43 M 10 1.4 9.2 8.7 43
11 58 M 20 1.1 14.6 6.0 49
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Fig. 2. Immunohistochemical staining with
heparan sulfate (HS) 10E4 antibody. (A) A
glomerulus from a nondiabetic subject that
demonstrates a linear staining pattern in the
glomerular basement membrane and mesan-
gial area (3400, score 5 4). (B) A glomerulus
from a patient with diabetic nephropathy with
moderate mesangial expansion that shows di-
minished staining (3400, score 5 2). (C) A
glomerulus from a patient with diabetic ne-
phropathy with severe mesangial expansion
that shows that the staining intensity was to-
tally diminished (3400, score 5 0).
Yokoyama et al: Heparan sulfate concentration in diabetes656
is unable to examine the qualitative changes in terms of
sulfation within the HS polysaccharide chains [37].
The significant decrease in urinary 10E4-binding HS
of patients with diabetes and nephropathy, with no or
small differences in serum and urinary 3G10-binding HS,
and in serum 10E4-binding HS, may point to a reduced
sulfation of HS within the GBM in diabetic nephropathy,
whereas the concentration of HS chains per se within
the GBM is rather preserved. This was supported by
the immunohistochemical staining with these antibodies,
while the lack of urine specimens in subjects who under-
went kidney biopsies necessitates future studies to inves-
tigate the correlation between glomeruli HS and urineFig. 3. Score of intensity of human glomeruli stained immunohisto-
HS. It is presumed that a decrease of HS N sulfationchemically with heparan sulfate (HS) 10E4 antibody in nondiabetic
subjects (subjects 1 through 3), diabetic subjects with normoalbuminu- within the GBM, being reflected by urinary 10E4 binding
ria (subjects 4 through 6) and overt proteinuria (subjects 7 through 11). HS, leads to the loss of GBM charge selectivity. A recentData are mean 6 sem.
report indicated increased urinary excretion of type IV
collagen and laminin in patients with diabetes and fur-
thermore increased in patients with diabetic nephropa-
thy compared with control subjects [38]. Taken together,suggest an amount of HS saccharide units [27]. There-
alterations of ECM protein components excreted in thefore, the decreased 10E4-binding HS excretion with a
urine appear to reflect basement membrane metabolism.preserved 3G10-binding HS may suggest that the degree
One reason for the considerable overlap of urinaryof HS N sulfation in urine was affected by the presence
10E4 HS between the groups may be the intraindividualof diabetes and was more affected by the development
variation in the urinary 10E4 HS excretion rate. Theof nephropathy. Whether the decreased urinary excre-
coefficient variation (day to day and time to time withintion of 10E4-binding HS seen in diabetic patients without
a day) was 20 to 30%, which was similar to that observedovert nephropathy is an early marker for the develop-
in the AER. Although the quantitation of the amountsment of diabetic nephropathy needs to be evaluated in
of HS chains by ELISA itself may not be sensitivea prospective study.
enough as a marker for the charge barrier of the GBM,Thus far, simultaneous measurements of both serum
it could not exclude implications of the decreased urinaryand urinary concentrations of HS using antibodies spe-
10E4 HS excretion with regard to the pathophysiologicalcific for HS chains have not been reported in diabetic
ECM alterations within the GBM contributing to theanimals nor in human subjects. We have confirmed the
development of diabetic nephropathy.
specificity of mAbs 10E4 and 3G10 for binding to HS
Other possibilities to explain the decrease of urinary
in the ELISA. Several studies investigated concentra- 10E4-binding HS in patients with diabetic nephropathy
tions of GAGs and HS only in the urine of diabetic include an increased degradation of HS within the GBM
patients or rats [29–37]. The measurements of GAGs or in the urine. HNO2, which is known to cleave N-sul-were performed using the cellulose acetate membrane fated sequences of HS [39], is one of the degradation
electrophoresis [29–31] or using the alcian blue method products of nitric oxide (NO) [40]. A recent report indi-
[32–35]. These studies showed increased urinary excre- cated that endothelial cell-derived NO degraded heparin
tion of GAGs in diabetic subjects [29–37]. However, and HS via HNO2 [41]. Tissue damage from inflamma-
these measurements included several kinds of GAGs tory processes may release excess NO, and such condi-
such as chondroitin sulfate, dermatan sulfate, and hyalur- tion may take place in the GBM of diabetic nephropathy
onic acid in addition to HS. It is unknown which GAG [42, 43]. A decreased 10E4-binding HS value as a result
may be affected by diabetes. Bernard et al mentioned of blocking of the epitope by a component present in
that the total amount of urinary GAG is not related to the urine is unlikely, as the addition of glucose or BSA
albuminuria and is an unreliable marker for glomerular did not affect the reactivity of 10E4 with HS (data not
damage [34]. A finding by McAuliffe et al, who showed shown). Concentrations of NaCl .0.15 m and pH values
a decreased ratio of HS/total GAG excretion in patients .7.6, which are known to inhibit the reactivity of 10E4
with diabetic nephropathy as compared with patients with HS [27], would not take place in the urine or serum
with normoalbuminuria and microalbuminuria, appears diluted with PBS-TB. Likewise, a major effect of medica-
to be consistent with our finding, although their method tion is also unlikely because the use of antihypertensive
to measure HS using ion exchange chromatography [37] agents or antihyperlipidemic agents had no influence on
the values of 10E4-binding HS. There were approxi-may also include hyaluronic acid and keratan sulfate and
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Trends Biochem Sci 11:221–225, 1986is different from HS present in the serum or in the urine,
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